The life science company Sartorius acquired U.S.‑based purification expert WaterSep BioSeparations LLC through its subgroup Sartorius Stedim Biotech. WaterSep BioSeparations develops, manufactures and markets hollow‑fiber membrane devices and pre-sterilized assemblies for upstream and downstream biopharmaceutical applications. The privately-owned company based in Marlborough, Massachusetts, USA, employs around 15 people and is expected to earn revenue of approximately 2.5 million U.S. dollars in 2020 at strong growth rates and a substantial double-digit EBITDA margin. The parties agreed on a purchase price of approximately 27 million U.S. dollars plus an earn‑out component of up to 9 million U.S. dollars, depending on the achievement of defined sales revenue growth by 2023.
“This acquisition nicely complements our current offering for cell and gene therapy applications, cell harvesting and various solutions for intensified bioprocessing,” said Dr. René Fáber, Head of the Sartorius Bioprocess Solutions Division and Executive Board member. “I am pleased to welcome the WaterSep team to Sartorius and look forward to jointly introducing WaterSep BioSeparations innovative solutions to our customers.”
“With Sartorius' strong emphasis on cost- and time-saving bioprocessing, it is the ideal partner to accelerate the adoption of our extensive single-use crossflow product offerings. WaterSep is excited to join the Sartorius team as they continue to lead the transformation of bioprocessing to single use,” said Attila Herczeg, CEO and President of WaterSep BioSeparations.